← OncoDesk·MedDesk·web edition — reference only, not medical advice
all sections · full handbook

1Breast

Snapshot. Two axes decide everything. SUBTYPE — from ER/PR, HER2 and Ki-67 — sorts into HR+/HER2−, HER2+, TNBC, or HER2-low/ultralow, and picks which drugs. STAGE — I–II early, III locally advanced, IV metastatic — picks the intent and sequence (surgery-first, neoadjuvant, or palliative). You need both.
Workup
Triple assessment — exam + imaging + CORE biopsy mammogram + breast ultrasound; add MRI for lobular / dense breast / occult primary · core, NOT FNA (fine-needle aspiration) — you need architecture, grade and receptors
The biopsy must report → grade + ER/PR + HER2 + Ki-67 ER/PR ≥1% = positive · HER2 by IHC (immunohistochemistry) 0–3+, with 2+ → reflex FISH (fluorescence in situ hybridization) · ASCO/CAP criteria
Axilla → ultrasound ± sentinel node biopsy gives the N-stage
⚠ Systemic staging ONLY if node-positive, stage III, or symptomatic CT chest/abdo/pelvis + bone scan, or PET/CT — not routine in early disease
Genomic assay (Oncotype DX / MammaPrint) → decides adjuvant chemo in node-negative or 1–3-node-positive HR+/HER2− disease
METASTATIC → the biomarkers that pick the drug PD-L1 (CPS) in TNBC — gates pembrolizumab · ctDNA at PROGRESSION for ESR1 (emerges under AI pressure → elacestrant), PIK3CA / AKT1 / PTEN (→ capivasertib or alpelisib) · HER2-low / ultralow on IHC — re-read the original block, it is not a new test
Germline BRCA1/2 (± multigene panel) ASCO/SSO 2024: all women <65 with new stage I–III or de-novo stage IV; at ≥65 if a PARP-inhibitor candidate, TNBC, male, or suggestive personal/family history; and any recurrence being considered for a PARP inhibitor · ⚠ NCCN is narrower (≤50 all-comers, ≤65 if TNBC, plus other hereditary criteria) · also drives the operation (bilateral mastectomy discussion), risk-reducing salpingo-oophorectomy, and family cascade testing
Treatment by setting
SettingTreatment
HR+/HER2−
early / locally advanced
Backbone at EVERY stage: surgery → radiotherapy → adjuvant endocrine therapy 5–10 yr lumpectomy or mastectomy + axillary staging · whole-breast RT after lumpectomy (may be omitted in older women with small node-negative tumours), post-mastectomy / nodal RT if node-positive or high-risk · endocrine = tamoxifen (premenopausal) or an aromatase inhibitor ± ovarian suppression (postmenopausal). This is the least chemo-sensitive subtype — endocrine therapy is the main event; chemo is selective.
Stage I (T1 N0) → surgery first, and chemo is usually NOT needed a genomic assay makes the chemo call — Oncotype RS ≥26 → chemo; most small node-negative tumours skip it (TAILORx)
Stage II / node-positive (operable) → surgery first → then adjuvant therapy neoadjuvant rarely earns its place here (HR+ downstages poorly) — operate, then treat · chemo decided by assay in 1–3-node disease (RxPONDER), and when given chemo = dose-dense AC→T (doxorubicin + cyclophosphamide → a taxane; lower-risk alternative TC = docetaxel + cyclophosphamide) · node-positive high-risk → add adjuvant CDK4/6 inhibitor (abemaciclib 2 yr (monarchE) · ribociclib 3 yr (NATALEE)) · germline BRCA + high-risk → add adjuvant olaparib ×1 yr (OlympiA) (the HR+ bar is high: ≥4 nodes, or CPS+EG ≥3 residual)
Stage III (locally advanced, T3–4 / N2–3) → neoadjuvant AC→T FIRST → surgery → RT → adjuvant endocrine + the escalations above a pathological complete response is uncommon in HR+, but neoadjuvant still downstages the breast and axilla and exposes residual disease to guide the CDK4/6 and olaparib decisions
HR+/HER2−
metastatic
1st line → endocrine therapy (an AI or fulvestrant) + a CDK4/6 inhibitor almost everyone · palbociclib / ribociclib / abemaciclib · biomarker-driven throughout — test ctDNA (circulating tumour DNA) / tissue, and the mutation picks the drug
Exception → inavolisib + palbociclib + fulvestrant (INAVO120) PIK3CA-mutant AND relapsed ≤12 mo on adjuvant endocrine therapy — already endocrine-resistant, PI3K driving it
On progression → re-test ctDNA and match the mutation
ESR1-mutant → elacestrant (EMERALD) an oral SERD · ESR1 emerges under the AI's pressure
PIK3CA / AKT1 / PTEN altered → capivasertib (CAPItello-291) or alpelisib (SOLAR-1) capivasertib targets AKT — covers all three · alpelisib is PIK3CA-only
Germline BRCA → a PARP inhibitor
Later → single-agent chemotherapy, or an ADC chemo = capecitabine, a taxane, eribulin, or vinorelbine · ADC = T-DXd if HER2-low, or sacituzumab govitecan (a Trop-2 ADC)
HER2+
early / locally advanced
Stage I, small (T1a–b N0, ≤~2 cm node-negative) → surgery → adjuvant paclitaxel + trastuzumab the de-escalated APT regimen — weekly paclitaxel ×12 + trastuzumab to 1 yr; no anthracycline, no pertuzumab
Stage II–III (≥T2 or node-positive) → neoadjuvant TCHP → surgery → locoregional RT → adjuvant trastuzumab ± pertuzumab to 1 yr TCHP = docetaxel + carboplatin + trastuzumab + pertuzumab · surgery = lumpectomy/mastectomy + axillary staging · keep pertuzumab adjuvantly if node-positive (APHINITY)
Residual disease at surgery → switch adjuvant to T-DXd trastuzumab deruxtecan — beat T-DM1 (DESTINY-Breast05), which had itself beaten trastuzumab for residual disease (KATHERINE) · recent change — confirm your NCCN version reflects it
HR+/HER2+ high-risk → extended adjuvant neratinib (ExteNET)
⚠ Anti-HER2 needs adequate LVEF left-ventricular ejection fraction — significant cardiac dysfunction → cardio-oncology co-management rather than automatic exclusion
HER2+
metastatic
1st line → T-DXd + pertuzumab (DESTINY-Breast09) new benchmark, replacing taxane + trastuzumab + pertuzumab (THP) where available · very recent approval — confirm local/formulary adoption before treating on this basis
If THP used 1st line → 2nd line T-DXd
3rd line → tucatinib + trastuzumab + capecitabine brain-active
TNBC
early / locally advanced
Stage I, small (cT1a–b N0) → surgery → adjuvant chemo an anthracycline + taxane; the very small node-negative tumours do not need the full neoadjuvant immunotherapy regimen
Stage II–III (cT2+ or node-positive — NCCN prefers neoadjuvant from cT1c N+) → neoadjuvant pembrolizumab + chemo → surgery → locoregional RT → adjuvant pembrolizumab the KEYNOTE-522 regimen = carboplatin + paclitaxel → then AC, all with pembrolizumab (a PD-1 checkpoint inhibitor), then pembrolizumab alone after surgery (KEYNOTE-522)
Residual disease after neoadjuvant → adjuvant capecitabine
Germline BRCA → adjuvant olaparib (OlympiA) a PARP (poly-ADP-ribose polymerase) inhibitor · ≥pT2 or ≥pN1 after adjuvant chemo, or any residual disease after neoadjuvant chemo
TNBC
metastatic
PD-L1-positive → pembrolizumab + chemo programmed death-ligand 1, CPS-based
Germline BRCA → a PARP inhibitor
Later → sacituzumab govitecan (ASCENT) a Trop-2 ADC (antibody-drug conjugate)
HER2-low / ultralow
metastatic only
T-DXd after ≥1 line of endocrine therapy HER2-low = IHC 1+, or 2+/ISH− (DESTINY-Breast04)
extended to HER2-ultralow = IHC 0 with faint incomplete staining (DESTINY-Breast06)
Regimens
AC→T = two blocks back-to-back: AC (doxorubicin [an anthracycline] + cyclophosphamide) ~4 cycles first, then switch to a taxane (paclitaxel/docetaxel) for the second block — ≈5–6 months total. Dose-dense = every 2 weeks + G-CSF (granulocyte colony-stimulating factor; higher-risk/node-positive). TC = docetaxel + cyclophosphamide (anthracycline-free). TCHP = docetaxel + carboplatin + trastuzumab + pertuzumab (HER2+).
Watch
T-DXd → ILD (interstitial lung disease) / pneumonitis — new cough/dyspnoea, hold + HRCT (high-resolution CT). Anti-HER2 → fall in LVEF, serial echo. CDK4/6 inhibitors → neutropenia; ribociclib → QTc (corrected QT-interval) prolongation. PI3K/AKT inhibitors (alpelisib, capivasertib, inavolisib) → hyperglycaemia, plus rash/diarrhoea (capivasertib) or stomatitis (inavolisib). PARP inhibitors → cytopenias, rare secondary MDS/AML (myelodysplastic syndrome/acute myeloid leukaemia).
Lung →